The Use of Primidone in Neonates with Theophylline-Resistant Apnea

Christopher A. Miller, Mark Gaylord, Vichien Lorch, Andrew W. Zimmerman

Research output: Contribution to journalArticlepeer-review

Abstract

Objective. —To determine whether primidone reduced the occurrence of apnea of prematurity in neonates with apnea resistant to theophylline. Design. —Retrospective review. Setting. —Neonatal intensive care unit. Participants. —Sixteen premature infants (mean age, 27.8 weeks) in whom apnea and bradycardia recurred despite therapeutic levels of theophylline. Six of the patients were receiving assisted ventilation. Intervention. —Administration of primidone (10 to 15 mg/kg per day) orally or by nasogastric tube at a mean age of 35 days. Results. —Apnea and bradycardia decreased significantly 24 to 72 hours after initiation of primidone treatment (by 68% and 69%, respectively) compared with pretreatment events. We obtained similar results after a separate analysis of the 10 patients who had been weaned from assisted ventilation before treatment with primidone. No toxic reactions were observed. Conclusions. —Primidone represents a possible adjuvant therapy in theophylline-resistant apnea of prematurity. Caution is advised, because of primidone's complex pharmacologic characteristics, until there are further controlled prospective studies.

Original languageEnglish (US)
Pages (from-to)183-186
Number of pages4
JournalAmerican Journal of Diseases of Children
Volume147
Issue number2
DOIs
StatePublished - 1993
Externally publishedYes

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Fingerprint Dive into the research topics of 'The Use of Primidone in Neonates with Theophylline-Resistant Apnea'. Together they form a unique fingerprint.

Cite this